What is Parmax Pharma share price return in the past 10 years?

Data is not available for this company

Parmax Pharma Ltd - Stock Valuation and Financial Performance

Name: Parmax Pharma
Brand: Parmax Pharma

BSE: 540359 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Parmax Pharma Share Price

₹48.25 -0.73 -1.49%
as on 21-Nov'24 16:59

DeciZen - make an informed investing decision on Parmax Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Parmax Pharma stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

18.3 Cr.

52-wk low:

24.2

52-wk high:

Is Parmax Pharma Ltd an attractive stock to invest in?

1. Is Parmax Pharma Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Parmax Pharma Ltd is a below average quality company.

2. Is Parmax Pharma Ltd undervalued or overvalued?

The key valuation ratios of Parmax Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Parmax Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Parmax Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Parmax Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0.9%	0.3%	0.2%	0.8%	2%	10.2%	16.3%	6.6%	4%	-59.9%	-
Value Creation Index ⓘ	-0.9	-1.0	-1.0	-0.9	-0.9	-0.3	0.2	-0.5	-0.7	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	11.9	12	20.9	26.2	18.2	15.4	11	17
Sales YoY Gr.	-	NA	NA	NA	0.9%	74.3%	25.1%	-30.3%	-15.6%	-28.4%	-
Adj EPS ⓘ	0	-0	-0	0	0.2	0.8	1.5	0.3	-0.2	-11.3	-12.2
YoY Gr.	-	-125%	NA	NA	NA	460%	76.2%	-81.1%	-171.4%	NA	-
BVPS (₹) ⓘ	8.2	8	7.1	6.1	5.2	7.4	10.5	11.9	12.7	-1.7	-1.7
Adj Net Profit ⓘ	0	0	0	0	0.1	0.4	0.8	0.1	-0.1	-5.8	-5
Cash Flow from Ops. ⓘ	-0.1	0	-0.5	3.9	0.9	2.8	3.5	0.8	0.3	-0.2	-
Debt/CF from Ops. ⓘ	-13.4	-94.8	-2	0.6	6	1.9	1.7	6.9	16.1	-31.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	-1.7%	-25.1%	-28.4%
Adj EPS ⓘ	-287.3%	-337.5%	-297.1%	NA
BVPSⓘ	-184.1%	-180.1%	-154.6%	-113.5%
Share Price	-	21.6%	5.6%	53.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	0.6	-0.1	-0.2	0	1.7	8.9	13.9	2.4	-1.8	-195	719.2
Op. Profit Mgn % ⓘ	0	0	0	9.1	9.3	8.5	13.1	14	14.7	-30.6	-12.6
Net Profit Mgn % ⓘ	0	0	0	0	0.7	2.1	2.9	0.8	-0.7	-52.4	-26.1
Debt to Equity ⓘ	0.2	0.1	0.3	0.7	2.1	1.5	1.3	1	1	83.3	-
Working Cap Days ⓘ	0	0	0	182	241	135	110	136	154	218	63
Cash Conv. Cycle ⓘ	0	0	0	-60	-185	-83	-72	-81	-35	5	-22

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 719.20%

Sales growth is good in last 4 quarters at 110.32%

Sales growth has been subdued in last 3 years -25.06%

Debt to equity has increased versus last 3 years average to 83.26

Latest Financials - Parmax Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-12.2	-
TTM Sales (₹ Cr.)	17.5	-
BVPS (₹.) ⓘ	-1.7	-
Reserves (₹ Cr.) ⓘ	-4	-
P/BV ⓘ	-29.23	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	24.18 / 54.00
All Time Low / High (₹)	12.50 / 81.90
Market Cap (₹ Cr.)	18.3
Equity (₹ Cr.)	3.7
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Parmax Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Parmax Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Parmax Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	0	0	0	11.89	12	20.92	26.18	18.24	15.40	11.02
Operating Expenses ⓘ	0.02	0.05	0.05	10.80	10.88	19.15	22.76	15.68	13.14	14.39
Manufacturing Costs	0	0	0	2.31	2.74	3.60	4.14	3.91	3.35	3.06
Material Costs	0	0	0	5.78	5.20	11.27	13.43	6.71	5.49	7.05
Employee Cost	0	0	0	2.13	2.10	2.93	3.58	3.52	2.81	2.92
Other Costs ⓘ	0.02	0.04	0.05	0.57	0.85	1.36	1.61	1.55	1.49	1.36
Operating Profit ⓘ	-0.02	-0.05	-0.05	1.08	1.11	1.77	3.42	2.56	2.26	-3.37
Operating Profit Margin (%)	-	-	-	9.1%	9.3%	8.5%	13.0%	14.0%	14.7%	-30.6%
Other Income ⓘ	0.06	0.06	0.06	0.05	0.05	0.10	0.09	0.06	0.04	0.05
Interest ⓘ	0	0	0	0.04	0.03	0.13	0.36	0.39	0.37	0.62
Depreciation ⓘ	0	0	0	1.09	1.03	1.01	1.94	1.93	1.88	1.71
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0.04	0.01	0.01	0	0.10	0.73	1.21	0.30	0.05	-5.66
Tax ⓘ	0.01	0.02	0.01	0	0.02	0.30	0.45	0.16	0.15	0.12
Profit After Tax	0.02	0	-0.01	0	0.08	0.43	0.75	0.14	-0.10	-5.78
PAT Margin (%)	-	-	-	0.0%	0.7%	2.0%	2.9%	0.8%	-0.7%	-52.4%
Adjusted EPS (₹)	0.1	0.0	0.0	0.0	0.2	1.2	2.0	0.4	-0.3	-15.5
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	4.15	4.56	4.56	4.56	4.64	5.06	5.82	5.96	5.86	0.07
Share Capital ⓘ	4.03	4.45	4.45	4.45	4.45	4.45	4.45	4.45	4.45	4.45
Reserves ⓘ	0.12	0.11	0.10	0.11	0.18	0.61	1.37	1.51	1.40	-4.38
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0.79	0.46	1.02	1.96	5.26	5.03	5.43	4.52	4.48	5.91
Long Term Debt	0.79	0.46	1.02	1.96	5.26	5.03	5.43	4.52	4.48	5.91
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.01	0.01	2.09	9.65	9.19	9.62	9.92	5.52	4.66	7.39
Others Liabilities ⓘ	0.03	0.04	0.04	0.44	0.55	1.34	1.56	1.97	2.61	1.96
Total Liabilities ⓘ	4.97	5.08	7.71	16.60	19.63	21.06	22.73	17.97	17.61	15.33
Fixed Assets
Gross Block	2.53	2.53	2.73	6.96	7.04	9.64	15.92	17.45	18.38	19.87
Accumulated Depreciation	0	0	0	1.09	2.12	0	5.07	7	8.88	10.60
Net Fixed Assetsⓘ	2.53	2.53	2.72	5.86	4.92	9.64	10.84	10.44	9.50	9.27
CWIP ⓘ	0	0	0	0	3.33	0	0	0	0	0.10
Investmentsⓘ	0	0	0	0	0.20	0.20	0.20	0	0	0
Inventories	0	0	1.76	3.22	3.97	2.72	3.95	2.85	4.31	2.39
Trade Receivables	0.08	0.09	0.12	1.97	1.15	3.30	1.65	0.68	0.62	1.82
Cash Equivalents	0.21	0.31	0.17	0.96	1.57	1.77	2.55	1.05	0.41	0.05
Others Assetsⓘ	2.14	2.14	2.93	4.59	4.50	3.43	3.53	2.95	2.78	1.69
Total Assets ⓘ	4.97	5.08	7.71	16.60	19.63	21.06	22.73	17.97	17.61	15.33

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-0.06	0	-0.50	3.88	0.92	2.82	3.53	0.75	0.33	-0.19
PBT ⓘ	0.04	0.01	0.01	0	0.10	0.73	1.21	0.30	0.05	-5.66
Adjustment ⓘ	-0.01	-0.02	-0.01	1.07	0.96	0.86	1.65	1.72	1.69	1.59
Changes in Working Capital ⓘ	-0.08	-0	-0.5	2.6	-0.19	1.24	0.67	-1.27	-1.41	3.88
Tax Paid ⓘ	0	0	0	0.21	0.06	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	0	0	-0.19	-4.23	-3.41	-2.40	-3.15	-1.53	-0.94	-1.59
Capex	0	0	-0.19	-4.23	-3.41	-2.40	-3.15	-1.53	-0.94	-1.59
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activityⓘ	0	0.10	0.56	1.14	3.10	-0.23	0.40	-0.91	-0.04	1.43
Net Proceeds from Shares ⓘ	0.13	0.42	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0.13	-0.33	0.56	1.14	3.30	-0.23	0.40	-0.91	-0.04	1.43
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	-0.20	0	0	0	0	0
Net Cash Flow ⓘ	-0.06	0.09	-0.14	0.79	0.61	0.20	0.78	-1.69	-0.65	-0.35

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	0.7	-0.12	-0.28	0.02	3.71	18.19	22.55	3.38	-2.26	-281.14
ROCE (%)	0.88	0.28	0.18	0.81	1.96	10.19	16.25	6.62	3.96	-59.88
Asset Turnover Ratio	0	0	0	0.98	0.66	1.03	1.2	0.9	0.87	0.67
PAT to CFO Conversion(x)	-3	N/A	N/A	N/A	11.5	6.56	4.71	5.36	N/A	N/A
Working Capital Days
Receivable Days	0	0	0	32	47	39	35	23	15	40
Inventory Days	0	0	0	76	109	58	47	68	85	111
Payable Days	0	0	0	371	661	305	265	420	338	312

Parmax Pharma Ltd Stock News

Parmax Pharma Ltd FAQs

What is the share price of Parmax Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Parmax Pharma on 21-Nov-2024 16:59 is ₹48.25.

What is the market cap of Parmax Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Parmax Pharma stood at ₹18.32.